Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder

A. Pavlotsky,A. Eidelman,F. Barak,Haim Alon,Y. Horn
DOI: https://doi.org/10.1002/jso.2930410106
1989-05-01
Journal of Surgical Oncology
Abstract:We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2‐week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity‐related symptoms. Cystoscopic follow‐up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.
What problem does this paper attempt to address?